Insider Selling: Arcus Biosciences (NYSE:RCUS) CFO Sells $132,073.60 in Stock

Arcus Biosciences, Inc. (NYSE:RCUS) CFO Robert Goeltz II sold 5,960 shares of the business’s stock in a transaction that occurred on Wednesday, December 17th. The shares were sold at an average price of $22.16, for a total transaction of $132,073.60. Following the transaction, the chief financial officer owned 74,476 shares of the company’s stock, valued at approximately $1,650,388.16. This represents a 7.41% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Arcus Biosciences Stock Performance

RCUS opened at $21.99 on Friday. The firm’s fifty day moving average is $21.10 and its two-hundred day moving average is $14.16. The firm has a market cap of $2.37 billion, a PE ratio of -6.39 and a beta of 0.75. Arcus Biosciences, Inc. has a twelve month low of $6.50 and a twelve month high of $26.40. The company has a debt-to-equity ratio of 0.22, a quick ratio of 3.65 and a current ratio of 3.65.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings results on Tuesday, October 28th. The company reported ($1.27) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.33) by $0.06. Arcus Biosciences had a negative net margin of 136.40% and a negative return on equity of 68.17%. The company had revenue of $26.00 million during the quarter, compared to analyst estimates of $19.89 million. During the same quarter in the previous year, the business earned ($1.00) EPS. The firm’s revenue was down 45.8% on a year-over-year basis. Equities research analysts anticipate that Arcus Biosciences, Inc. will post -3.15 EPS for the current year.

Key Stores Impacting Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Arcus will present at the 44th Annual J.P. Morgan Healthcare Conference on Jan. 14, 2026 — a high‑visibility forum that can accelerate investor interest, provide clinical/program updates and attract buy‑side attention ahead of catalysts. Arcus to Present at JPM
• Neutral Sentiment: Recent analyst notes are mixed-to-constructive: some firms raised price targets and UBS/Bank of America reaffirmed coverage, producing a consensus “Moderate Buy” and an elevated average target — this supports upside but depends on upcoming clinical and commercial news. MarketBeat analyst summary
• Negative Sentiment: Significant, clustered insider selling occurred Dec. 16–18: CEO Terry Rosen sold large blocks (multiple filings totaling ~54k shares across two days), and other senior officers (CFO, COO, President, CAO, General Counsel and others) also sold shares — this concentrated executive selling is likely weighing on sentiment and may prompt short‑term selling pressure. See CEO SEC filing for details. CEO Form 4
• Negative Sentiment: Additional insider sales (CAO Alexander Azoy, CFO Robert Goeltz II, COO Jennifer Jarrett, President Juan Jaen, General Counsel Carolyn Tang, and insider Richard Markus) were filed and aggregated to meaningful dollar amounts — investors often interpret broad leadership selling as a negative signal even when trades may be for diversification or tax reasons. InsiderTrades summary

Hedge Funds Weigh In On Arcus Biosciences

A number of large investors have recently bought and sold shares of RCUS. Vanguard Group Inc. grew its stake in shares of Arcus Biosciences by 24.1% during the 1st quarter. Vanguard Group Inc. now owns 6,687,800 shares of the company’s stock worth $52,499,000 after acquiring an additional 1,298,584 shares in the last quarter. Woodline Partners LP boosted its holdings in Arcus Biosciences by 45.5% during the first quarter. Woodline Partners LP now owns 5,127,304 shares of the company’s stock worth $40,249,000 after purchasing an additional 1,603,367 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Arcus Biosciences by 14.9% during the second quarter. Geode Capital Management LLC now owns 1,596,329 shares of the company’s stock worth $12,995,000 after purchasing an additional 207,097 shares during the last quarter. Bank of America Corp DE grew its position in Arcus Biosciences by 173.5% in the third quarter. Bank of America Corp DE now owns 1,360,781 shares of the company’s stock valued at $18,507,000 after purchasing an additional 863,162 shares in the last quarter. Finally, Wellington Management Group LLP increased its stake in Arcus Biosciences by 35.3% in the 3rd quarter. Wellington Management Group LLP now owns 1,266,289 shares of the company’s stock valued at $17,222,000 after buying an additional 330,268 shares during the last quarter. Institutional investors and hedge funds own 92.89% of the company’s stock.

Analyst Upgrades and Downgrades

RCUS has been the subject of several recent analyst reports. Citigroup restated a “buy” rating on shares of Arcus Biosciences in a report on Friday, December 12th. Wells Fargo & Company boosted their price objective on Arcus Biosciences from $25.00 to $29.00 and gave the company an “overweight” rating in a research report on Monday, October 20th. Wedbush set a $35.00 target price on Arcus Biosciences and gave the stock an “outperform” rating in a research note on Wednesday, October 29th. Truist Financial set a $30.00 price target on shares of Arcus Biosciences in a research note on Friday, December 12th. Finally, UBS Group reiterated a “buy” rating on shares of Arcus Biosciences in a report on Monday, December 15th. Eight analysts have rated the stock with a Buy rating, two have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $28.89.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.